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Abstract
Background: Lung cancer is the leading cause of cancer-related mortality, and new therapeutic options are urgently
needed. Non-small cell lung cancer (NSCLC) accounts for approximately 85 % of all lung cancers, with the current
standard regimen of care for NSCLC including chemotherapy with pemetrexed as a single agent or in combination
with platinum-based agents, e.g. cisplatin. Pemetrexed is a folic acid antagonist that inhibits the synthesis of precursor
nucleotides, whereas cisplatin directly induces DNA adducts, the repair of which is dependent on sufficiently high
nucleotide levels. In the clinical setting, the pemetrexed-cisplatin combination therapy is administered concomitantly.
We hypothesized that prolonged pretreatment with pemetrexed could be beneficial, as prior depletion of nucleotide
pools could sensitize cancer cells to subsequent treatment with cisplatin.
Methods: NSCLC A549 and H460 cells were treated with pemetrexed for 72 h. In addition, 24 h of cisplatin treatment
was initiated at day 1, 2 or 3 resulting in either simultaneous pemetrexed application or pemetrexed pretreatment for
24 or 48 h, respectively. Cell growth and colony formation as well as senescence induction were quantified after
treatment. Cell cycle distribution and phosphorylation of histone variant H2AX as a surrogate marker for DNA
damage was quantified by flow cytometry. Relative changes in gene expression were determined by quantitative
real time PCR.
Results: Prolonged pemetrexed pretreatment for 48 h prior to cisplatin treatment maximally delayed long-term
cell growth and significantly reduced the number of recovering clones. Moreover, apoptosis and senescence were
augmented and recovery from treatment-induced DNA damage was delayed. Interestingly, a cell population was
identified that displayed an epithelial-to-mesenchymal transition (EMT) and which had a stem cell phenotype. This
population was highly resistant to concomitant pemetrexed-cisplatin treatment but was sensitized by pemetrexed
pretreatment.
Conclusions: Adaptation of the standard treatment schedule to include pretreatment with pemetrexed optimizes the
anticancer efficiency of pemetrexed-cisplatin combination therapy, which correlates with a persistence of treatment-
induced DNA damage. Therefore, this study warrants further investigations to elucidate whether such an adaptation
could enhance the effectiveness of the standard clinical treatment regimen. In addition, a subpopulation of therapy
resistant cells with EMT and cancer stem cell features was identified that was resistant to the standard treatment
regimen but sensitive to pemetrexed pretreatment combined with cisplatin.
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Background
Lung cancer is the leading cause of cancer-related mortal-
ity, resulting in over 1 million deaths each year worldwide.
This is mainly due to the difficulty of early detection and a
lack of successful treatment methods, thus more effective
therapy options are needed. Non-small cell lung cancer
(NSCLC) accounts for approximately 85 % of all lung can-
cers, and standard chemotherapy for NSCLC includes
pemetrexed (multitargeted antifolate, MTA; commercial
name ‘Alimta’), as a single agent or in combination therapy
(reviewed in [1]). The combination of MTA with cisplatin
was recently recommended as the gold standard therapy
for adenocarcinoma lung cancer patients with good
performance status [2]. In addition, MTA-cisplatin
combination therapy is also the recommended treat-
ment regimen for malignant pleural mesothelioma
(MPM) (reviewed in [3].
MTA is a folic acid antagonist inhibiting the synthesis of
precursor purine and pyrimidine nucleotides required for
DNA and RNA synthesis. MTA thereby interferes with
the proliferation and survival of replicating cancer cells.
Prolonged treatment with MTA induces replicative stress
in the form of single stranded DNA, which, if not
repaired, can lead to the formation of double stranded
DNA breaks [4]. Cisplatin mainly induces intrastrand
crosslinks and to a lesser extent also interstrand cross-
links. Repair of intrastrand crosslinks is mainly dependent
on functional nucleotide excision repair, which is impaired
upon nucleotide depletion [5].
Induction of DNA lesions or DNA replication stress
leads to the activation of the DNA damage response
(DDR) (reviewed in [6]). During DDR, phosphorylation
of histone variant H2AX (γH2AX) serves as a key medi-
ator for the assembly of DNA repair proteins at the sites
of DNA damage as well as for the activation of check-
point proteins. Consequently, analysis of γH2AX is fre-
quently used as a surrogate marker for DDR activation.
Prolonged cell cycle arrest after DNA damage induction
results at the molecular level in DNA double strand
break formation [7] and at the cellular level in a terminal
proliferation halt, i.e. senescence [8]. By permanently ar-
resting proliferation of damaged cells, senescence serves
as a barrier to cancer development.
An increasing body of evidence suggests that epithelial-
to-mesenchymal transition (EMT) plays a crucial role in
the tumorigenesis, drug resistance, relapse and metastasis
of various cancers (reviewed in [9]). Diverse stimuli can
lead to the activation of the EMT signaling cascade
thereby inducing the expression of mesenchymal markers,
e.g. vimentin. Furthermore, the expression of N-Cadherin
is associated with acquisition of EMT phenotype whereas
E-cadherin is associated with an epithelial phenotype
(reviewed in [9]). Cells can advance only partially through
the EMT program, resulting in a mixture of epithelial and
mesenchymal traits (reviewed in [9]). For example in
breast cancer, a hybrid epithelial/mesenchymal (hybrid E/
M) state was identified at the single cell level, which was
associated with increased mammosphere formation and
poor predicted outcomes in all breast cancer subtypes
[10]. In the context of lung cancer, it was shown that IL-6-
induced EMT increases adenocarcinoma tumor growth
and metastasis in vivo [11] and we have recently shown
that blocking EMT abrogates resistance to MTA in
NSCLC [12]. Mesenchymal cells are characterized by a
loss of cell-to-cell contact and a spindle-shaped morph-
ology (reviewed in [13]).
Expression of NANOG, Sox2, CD44 is associated with
stemness in various tissues and has allowed the identifica-
tion of normal stem cells and subsequently also of cancer
stem cells (CSCs; reviewed in [9]. For lung cancer, CSCs
were identified by means of numerous markers, e.g.
drug-resistant side-population, CD133+, ALDHhigh and
EpCAM+ cells (for references, see [14]). However, simi-
lar to the latest discoveries concerning the EMT status,
more recent findings indicate that increased plasticity
might also be present within cancer populations, enab-
ling bidirectional interconvertibility between CSCs and
non-CSCs (reviewed in [15]).
In this study, we aimed to optimize the MTA-cisplatin
anticancer modality and subsequently performed an in-
depth molecular and cellular analysis to elucidate the
molecular mechanisms underlying the observed benefit
of sequential combination therapy. We demonstrated
that prolonged MTA pretreatment improved the com-
bination therapy’s efficiency. This effect correlated with
the induction of persistent DNA damage, increased
apoptosis and senescence initiation. The occurrence of
resistant clones was thereby diminished, however those
that did remain featured an epithelial-to-mesenchymal
phenotype and were enriched for stem cell traits.
Methods
Cell culture and reagents
The NSCLC cell lines A549 (CCL-185) and H460 (HTB-
177) were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and cultured in
Dulbecco’s’ modified Eagle’s medium nutrient mixture F-
12 Ham (Cat. #D6421, Sigma-Aldrich, St. Louis, MO,
USA), supplemented with 10 % fetal bovine serum (Cat.
#10270-106; Life Technologies, Grand Island, NY, USA),
1 % Penicillin/Streptomycin solution (Cat. #P0781, Sigma-
Aldrich) and 1 % L-Glutamine (Cat. #25030-024, Sigma-
Aldrich) at 37 °C in a humidified 5 % CO2 incubator. Cell
lines were previously DNA fingerprinted (Microsynth,
Bern, Switzerland). Medium was changed every 3 days.
Pemetrexed/MTA (commercial name ‘ALIMTA’; Cat
#VL7640) was purchased from Eli Lilly (Suisse) S.A.
(Vernier/Geneva, Switzerland). Cisplatin (commercial
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name ´Cisplatin Ebewe´) was purchased from Sandoz
Pharmaceuticals AG (Steinhausen/Cham, Switzerland).
Drug response and senescence associated β-galactosidase
assay
To determine cell growth during the treatment and the
initial recovery phase, 1×106 cells were seeded into
150 mm × 20 mm tissue culture treated plates (Cat.
#20151, SPL Life Sciences Co., Ltd, Korea). Parallel experi-
ments were performed in triplicate and samples were sub-
sequently processed for flow cytometry as described
below. Starting at the day after seeding, i.e. day 0, cells
from one plate per treatment were harvested using Try-
pLE (Cat. #12604021, Invitrogen, Grand Island, NY, USA).
Cell titers were determined using a hemocytometer and
trypan blue (Sigma-Aldrich) (final concentration 0.1 %)
for dead cell exclusion. The cells were washed in
phosphate-buffered saline and processed for analysis by
flow cytometry as described below. Resistant clones on re-
covery day 10 were counted on a centered surface of
25 cm2, using a 5 mm × 5 mm grid for orientation. To de-
termine cell growth during the extended recovery period,
cells were harvested at day 10 of the recovery period,
reseeded at a density of 10’000 cells per 150 mm × 20 mm
plate and cell titers were subsequently determined as de-
scribed above. Experiments were repeated independently
three times.
Senescent cells were visualized by using the senes-
cence associated β-galactosidase assay (Cat. #20151, Cell
Signaling Technology, MA, USA). In detail, 2000 cells
were recovered at day 10 after each treatment and were
seeded in tissue culture treated 6-well plates, fixed at
day 17 and stained overnight according to the manufac-
tures protocol. An inverted light microscope (Eclipse
TS100, Nikon Instruments Inc., Melville NA, USA)
equipped with a 10x objective was used for visual quan-
tification of senescent cells. Experiments were repeated
independently three times.
Gene expression analysis
Total RNA was isolated and purified with RNeasy Mini Kit
(Cat. #74106, Qiagen, Hilden, Germany) and subsequent
reverse transcription performed using High Capacity
cDNA Reverse Transciption Kit (Cat. #4368814, Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer’s instructions. Conditions for reverse transcription:
10 min at 25 °C, 120 min at 37 °C, 5 s at 85 °C, hold at 4 °
C. Quantitative real-time PCR (qRT-PCR) analyses were
performed on a 7500 Fast Real-Time PCR System (Applied
Biosystems) with commercially available TaqMan “Assay
on Demand” primer/probes (Applied Biosystems) and Taq-
Man FastUniversal PCR Master Mix (Life Technologies).
TaqMan primer list: E-Cadherin (Hs01023894_m1), N-
Cadherin (Hs00983056_m1), Vimentin (Hs00185584_m1),
CD44 (Hs 01075861_m1 CD44), Oct4B (Hs 00742896_s1
POU5F1), NANOG (Hs04260366_g1), CD133 (Hs 0100
9254_m1 PROM1), H3F3A (Hs02598544_g1), PP1A (Hs04
194521_s1). qRT-PCR cycle conditions were as follows:
50 °C for 2 min, 95 °C for 10 min, 40 cycles of 95 °C for
15 s, 60 °C for 1 min. Gene expression was assessed by
ΔΔCt values of the target genes versus control genes
H3F3A and PP1A. Experiments were performed as
three technical replicates and repeated independently
three times.
Flow cytometry
For analysis by flow cytometry, cells were harvested as de-
scribed above. Subsequently, cells were washed with
phosphate-buffered saline, pH 7.4, fixed and perme-
abilized with Cytofix/Cytoperm solution (Cat. #554714,
BD Biosciences (San Jose, CA, USA)). Staining with
mouse Alexa Fluor 488 anti-γH2AX (Ser139) (Cat.
#613406, BioLegend, San Diego, CA, USA) antibody was
performed in phosphate-buffered saline (Pharmacy, Uni-
versity Hospital Bern, BE, Switzerland) supplemented with
0.5 % saponin (Sigma-Aldrich) and 1 % bovine serum al-
bumin (Sigma-Aldrich) on a rotating wheel (3 rpm) over-
night at 4 °C. Subsequently, cells were treated with
100 μg/ml RNase A (Sigma-Aldrich) and DNA was
stained simultaneously with 0.5 μg/ml 4’,6-diamidino-2-
phenylindole (DAPI) (Sigma-Aldrich). Cell fluorescence
was measured on a LSR2 upgraded flow cytometer (BD
Biosciences) and analyzed using FlowJo V10 (Tree Star,
Inc. (Ashland, OR, USA)). Flow cytometric analysis of the
different time points was performed in batches, e.g. cells
of the treatment period were analyzed first, followed by
the early recovery phase (rec d1-3), recovery day 6 and 10
and at last cells of recovery day 14. Each analysis was ac-
companied by an untreated control. Approximately 5 % of
the cells of the untreated controls were placed in the F/S-
high compartment and used as normalization standard to
compensate for variations in photomultiplier settings. Buf-
fer treated controls were used to set the gating threshold
for γH2AX to 5 % as describe before [16]. When indi-
cated, cells were labeled with 10 mM 5-ethynyl-20-deox-
yuridine for 60 min and stained (Alexa Fluor 647)
according to the manufacturer’s instructions (C35002; Life
Technologies).
To compensate for slight shifts in linear DAPI fluores-
cence intensity due to treatment-induced changes in
FSC/SSC signal intensity, gates for cell cycle distribution
analysis were adjusted according to the peak of the G1
subpopulation.
Statistical analysis
Data are presented as the mean ± standard deviation of at
least three independent experiments if not stated differ-
ently. Statistical differences were assessed using unpaired t
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test with Welch’s and P values < 0.05 were considered
significant.
Results
Optimization of treatment schedule potentiates MTA-
cisplatin anticancer efficacy
Three different treatment regimens were compared to
determine whether the effectiveness of the MTA-
cisplatin combination therapy is dependent on the
treatment schedule. The three regimens consisted of
continuous MTA (1 μM) treatment for 72 h (Fig. 1a) in
combination with cisplatin (10 μM) treatment for 24 h
at different intervals. In detail, cisplatin was applied at
0→ 24 h (treatment #1), 24→ 48 h (treatment #2) or
48→ 72 h (treatment #3) relative to the 72 h of MTA
treatment (Fig. 1a). The doubling time (day 0→ 3) of
untreated A549 cells was approximately 22 h (Fig. 1b),
which is in agreement with the information provided by
the American Type Culture Collection. Single MTA
treatment (treatment #2, 24 h time point and treatment
#3, 24 h and 48 h time points, respectively) decreased
cell proliferation compared to untreated cells (Fig. 1b).
Cell numbers decreased during the 24 h of concomitant
MTA-cisplatin treatment (treatment #1, day 0→ 1)
whereas cell numbers initially still increased during MTA-
cisplatin co-treatment when preceded by MTA treatment
(treatment #2, day 1→ 2 and treatment #3, day 2→ 3).
After termination of the chemotherapy regimens (day 3),
cell numbers steadily increased from low levels after treat-
ment #1 during the early recovery phase (recovery day
0→ 14) whereas cell growth did not recover after treat-
ment #2 and, starting from recovery day 1, decreased after
treatment #3 (recovery day 1→ 14) (Fig. 1b).
At day 10 of the recovery phase, the absolute cell counts
were similar among the three different treatment regimens
(Fig. 1b). Visual examination of the recovered cells re-
vealed that clones formed by small, cuboid cells could be
distinguished from the surrounding monolayer of large
cells with a senescent phenotype (discussed below; Fig. 1c).
The clones consisting of small cells could be further di-
vided into two categories, i.e. small clones (10–300 cells)
and large clones (300–2000 cells). The number of clones
differed significantly among the different treatment regi-
mens. In detail, approximately 4 times as many small
clones were present after treatment #1 (305 +/-21) com-
pared to treatment #3 (77 +/-3.7; treatment #2 224 +/-13)
(Fig. 1c). Of note, numerous large clones were present
after treatment #1 (17 +/-1.5) whereas only low numbers
of this type were present after treatment #2 (3.3 +/-0.9)
and none after treatment #3. Thus, although absolute
A549 cell numbers were similar at day 10 of the recovery
phase, only treatment #3 efficiently reduced the occur-
rence of both, small and large recovering clones. Indeed,
the increased efficiency of MTA pretreatment on cisplatin
toxicity was also confirmed in the NSCLC cell line H460,
which also contains an activating KRAS mutation. In de-
tail, at day 10 during the recovery phase, the number of
small recovering clones was significantly reduced after
treatment #2 (23 +/-1.5) compared to treatment #1
(188 +/-15) and further significantly decreased after
treatment #3 (1.0 +/-0.6) (Fig. 1e and Additional file 1:
Figure S1). Formation of large H460 clones was re-
duced after treatment #1 (4.3 +/-0.3) and completely
abolished after treatment #2 and #3, respectively. In
summary, only treatment #3 efficiently reduced the oc-
currence of both, small and large recovering clones in
both tested NSCLC cell lines.
To evaluate the growth capacity of the remaining cells,
the residual cells were harvested at day 10 of the recovery
phase and reseeded at low density. All tested treatment
regimens reduced plating efficiency compared to the un-
treated control (day 11) (Fig. 1d). At day 17 of the recov-
ery phase, cell numbers compared to untreated control
were 2.4, 8, 27 times lower after treatment #1/2/3, respect-
ively. In other words, long-term cell growth of A549 cells
was reduced by a factor of 11 after treatment #3 when
compared to treatment #1. Similarly, long-term cell
growth of H460 cells was reduced by a factor of 18 after
treatment #3 when compared to treatment #1 (Fig. 1f).
The doubling time of A549 cells during day 14→ 17 of
the recovery phase was comparable after treatment #1,
treatment #2 and the untreated control (19, 22.5 and 20 h,
respectively), whereas treatment #3 significantly prolonged
the doubling time of long-term recovering cells (37 h).
Prolonged MTA pretreatment and subsequent cisplatin
treatment induces senescence
As mentioned above, visual examination revealed that
the cells surrounding the recovering clones displayed
morphologic changes that are associated with senes-
cence, namely increased cell size and flattened shape
(Fig. 1c; reviewed in [17]). Detectable by flow cytometry,
increased forward (cell size) and side (cellular granular-
ity) scatter intensity (F/S-high; Fig. 2a and Additional file
2: Figure S2) is an additional characteristic associated
with senescence (reviewed in [18]). Flow cytometric ana-
lysis at day 10 and 14 of the recovery phase (without
reseeding) revealed that the highest ratio of F/S-high
versus F/S-low cells was observed after treatment #3. In
detail, the ratios of FS-high versus FS-low cells were 12,
14 and 15.5 after day 10 and 2.3, 7.3 and 24 after day 14
for treatment #1/2/3, respectively. In other words, at day
14 of the recovery phase (without reseeding), a signifi-
cant fraction of cells after treatment #1 restored normal
forward and side scatter intensity (F/S-low), which was
less pronounced after treatment #3 (31 % versus 7 %, re-
spectively, p > 0.01). To quantify senescence induction,
cells from recovery day 10 were reseeded at low density.
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Fig. 1 Optimization of the treatment schedule potentiates MTA-cisplatin anticancer efficacy. a Schedule of the three tested treatment regimens
differing in the duration of MTA pretreatment preceding cisplatin addition (see text for details). b Growth curves of A549 cells during the treatment
(0-3 days) and early recovery phase (up to 14 days post-treatment). c Representative images of large A549 clones (clones are indicated by
arrows: treatment #1, 2 clones on the top half of the image; treatment #2, clone on the top half of the image) and small clones (treatment
#1 clone on the bottom-right of the image; treatment #2, 1 clone on the bottom half of the image; treatment #3 one small clone visible)
at day 10 of the recovery phase. Clones consisting of cells with a small surface area are clearly distinguishable from the background consisting of cells
with an enlarged surface area. Quantification of clones was performed as described in the material and methods section. d A549 cells exposed to the
indicated treatment regimen were harvested at day 10 of the recovery phase, reseeded and cell numbers were determined at the indicated time
points. e Quantification of colony formation ability of H460 cells as described in C. f Cell growth of H460 cells during the extended recovery phase as
described in D. Data represent means of three independent experiments and bars indicate standard deviations. **, P < 0.01 and *, P < 0.05
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At day 17 of the recovery phase, quantification of
senescence-associated β-galactosidase (SA-β-Gal) activity
revealed that the fraction of SA-β-Gal-positive cells (in-
dicated by black arrows in Fig. 2b) was 3.5-fold higher
after treatment #3 compared to treatment #1 (Fig. 2c).
However, visual examination revealed that a fraction of
the cells was clearly proliferating (see also Fig. 1d) giving
rise to distinct colonies as described below.
Prolonged MTA pretreatment exacerbates cisplatin-induced
cell cycle arrest
Terminal cell cycle arrest is a classic hallmark of senes-
cence, and has been observed after treatment with
chemotherapy (reviewed in [17]). Therefore, we moni-
tored the cell cycle distribution of A549 cells during
and after combined treatment with MTA and cisplatin.
It was shown previously that the increase in cell size of
A549 cells after cisplatin treatment leads to a shift of
the characteristic G1-phase peak in the DNA histogram
plot, and an even more pronounced shift for the G2/M-
phase peak [19]. In agreement with these findings,
already at day 1 after treatment #1 the DAPI signal inten-
sity of F/S-high cells was increased compared to F/S-low
cells (Additional file 3: Figure S3). Thus, the populations
consisting of F/S-high cells and F/S-low cells were ana-
lyzed separately in our subsequent analyses (Additional
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Fig. 2 Prolonged MTA pretreatment augments cisplatin-induced senescence in A549 cells. a Forward and side scatter analysis by flow cytometry
(without reseeding) at day 10 (10d rec) and day 14 (14d rec) of the recovery phase. b Representative images of cells acquired by phase contrast-based
microscopy at day 17 of the recovery phase (reseeded at day 10). Arrows indicate cells which stain positive for senescence associated β-galactosidase
activity. c Quantification of senescent cells based on increased β-galactosidase activity b. Represented are three independent experiments and
bars indicate means and standard deviations. ***, P < 0.001, **, P < 0.01 and *, P < 0.05
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file 3: Figure S3). In our initial experiments, we deter-
mined the cell cycle distribution by analyzing the incorp-
oration of 5-ethynyl-2’-deoxyuridine (EdU), a nucleoside
analog of thymidine, which is incorporated into DNA dur-
ing replication. Treatment of A549 cells with 1 μM MTA
for 24 h or 48 h reduced the fraction of replicating cells,
i.e. EdU-positive cells, to 4.6 % and 0.7 %, respectively,
compared to 42 % in control cells (Additional file 4: Figure
S4). This is consistent with an earlier report showing
that treatment with 200 nM MTA for 24 h nearly com-
pletely abolished incorporation of thymidine analogues
in colorectal adenocarcinoma cells [20]. However, it is
challenging to accurately set the gates of the cell cycle
phases on a DNA histogram blot from a cell population
with an irregular cell cycle distribution, e.g. after MTA
treatment, without being able to identify replicating
cells by EdU incorporation. Our previous findings re-
vealed that H2AX phosphorylation levels after DNA
damage induction were enhanced during S-phase com-
pared to the G1-phase levels [21]. Hence, H2AX phos-
phorylation was plotted over DNA content as a “zebra
blot” (a feature of the software FlowJo) (Additional file
5: Figure S5), which allowed us to more accurately de-
termine the G1 to S- and the S to G2/M-borders of
the cell cycle phases from cell populations with
irregular cell cycle distributions, e.g. after drug treat-
ment (Additional file 6: Figure S6).
During the initial 72 h treatment phase, the fraction of
F/S-high cells was increased by all tested treatment regi-
mens although with different frequencies (Fig. 3 and
Additional file 2: Figure S2). MTA-cisplatin co-
treatment for 24 h (treatment #1, day 0→ 1) resulted in
a rapid depletion of F/S-low cells and accumulation of
the remaining F/S-low cells in S-phase, which was also
observed in the corresponding F/S-high cell fraction
(47 %; Fig. 3). In contrast, the fraction of F/S-high cells
was significantly less increased after MTA-alone treat-
ment for 24 h [treatment #2&3, day 0→ 1 (14 % and
13 %)] or 48 h [treatment #3, day 0→ 2 (27 %)]. MTA-
alone treatment for 24 h resulted in an early S-phase ar-
rest of F/S-low cells, whereas an accumulation in S-and
G2/M-phase was detectable in F/S-high cells. MTA-
alone treatment for 48 h increased the fraction of F/S-
low cells in S-phase, which was even more pronounced
for F/S-high cells. Thus, at the start of the cisplatin
addition during treatment #1 (untreated cells), 95 % of the
cells featured a F/S-low phenotype and mainly resided in
the G1-phase of the cell cycle. In contrast, at the start of
cisplatin addition during treatment #3 (day 2), 27 % of the
cells had a F/S-high phenotype and the majority of those
Fig. 3 Prolonged MTA pretreatment exacerbates cisplatin-induced cell cycle arrest and reduces the fraction of recovering cells. Flow cytometric
analysis was performed at the indicated time points and subpopulations featuring either increased forward and side scatter intensity (F/S-high) or
normal forward and side scatter intensity (F/S-low) were identified as indicated in Figure S2. Cell cycle analysis was performed as indicated in
Figure S6. Data shown are the mean values and standard deviations of three experiments. *Percentage of total cell population (mean from
three experiments)
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cells were arrested in S-phase. Interestingly, common to
all tested treatment regimens, a significant increase in the
fraction of F/S-high cells was observed at the end of the
24 h cisplatin treatment. Also common to all treatments,
cisplatin exposure triggered cell cycle progression, e.g.
during treatment #1, cells advanced from G1- to S-phase
whereas S-phase cells progressed to G2/M-phase during
treatment #3. At the end of treatment #1 (day 3), 97 % of
the cells featured a F/S-high phenotype and most cells
were arrested in S-phase. However, after treatment #3,
only 44 % of the total remaining cells featured a F/S-high
phenotype and a prominent arrest in the G2/M-phase was
observed in this subpopulation.
During the recovery phase from treatment #1, the frac-
tion of F/S-low cells steadily increased up to day 14
(30 %) and this subpopulation featured a normal cell
cycle distribution. However, the majority of cells (70 %)
maintained F/S-high phenotype at day 14 of the recovery
phase, an effect which was even more pronounced after
treatment #2&3 (90 % and 96 %). 14 days after comple-
tion of treatment #1, the majority of the F/S-high cells
were in the G2/M-phase (55 %) or acquired a DNA con-
tent larger than G2/M, i.e. an aneuploid DNA content
(20 %). The majority of the cells were also arrested in
the G2/M phase (55 %) 14 days after completion of
treatment #3. However, the fraction of F/S-high cells
with aneuploid DNA content (11 %) was ~2-fold re-
duced compared to treatment #1 (Fig. 3). In summary,
recovery of F/S-low fraction featuring a normal cell cycle
distribution was maximally delayed after treatment #3
and the remaining F/S-high cells (day14 rec) were pri-
marily arrested in the G2/M-phase.
Cell cycle analysis also revealed the appearance of a frac-
tion of cells containing sub-G1 DNA content, which is a
hallmark of cells undergoing apoptosis (reviewed in [22].
Most sub-G1 cells were observed 24 h after treatment end
(rec d1) in the F/S-low fraction, reaching about 10 % for
treatment #1, 19 % after treatment #2 and 29 % after treat-
ment #3. The higher frequency of apoptotic cells after
treatment #3 is in agreement with the cell growth analysis
(Fig. 1b), which indicates a steady decrease in cell num-
bers during the recovery phase after treatment #3 but not
after treatment #1 & #2.
Prolonged MTA pretreatment results in persistent DNA
damage accumulation
We have previously demonstrated that accumulation of
persistent DNA damage leads to a cell cycle arrest and
induction of senescence in A549 cells [23]. Thus, we de-
termined the effect of the different treatment regimens
on H2AX phosphorylation, a marker of DNA damage.
After MTA-cisplatin co-treatment (treatment #1), H2AX
was rapidly phosphorylated (day 1) in the majority of F/
S-low cells during the S- and G2/M-phase, to a lesser
extend in G1 cells, which was even more pronounced in
F/S-high cells (Fig. 4). MTA-alone treatment for 24 h
(treatment #2&3, day 1) did not result in robust H2AX
phosphorylation in F/S-low cells whereas approximately
one third of the F/S-high cells in the S- and half of G2/
M-phased stained positive for γH2AX. However, MTA
treatment for 48 h (treatment #3, day 2) further in-
creased H2AX phosphorylation in the remaining F/S-
low fraction and H2AX phosphorylation was increased
in nearly 100 % of the F/S-high cells. Surprisingly, subse-
quent MTA-cisplatin co-treatment for an additional
24 h (treatment #3, day 3) reduced the fraction of
γH2AX positive cells in both the F/S-low and F/S-high
subpopulations compared to 48 h MTA-alone treatment
(treatment #3, day 2).
During the recovery from treatment #1, H2AX phos-
phorylation in the F/S-low cells steadily decreased in all
cell cycle phases, reaching nearly basal levels by day 10.
In contrast, 10 days after treatment #3, H2AX phosphor-
ylation was still detectable in over 50 % of the S/G2/M-
phase cells of the F/S-low subpopulation. Strikingly, in
all three F/S-high subpopulations, γH2AX phosphoryl-
ation was still increased in more than 90 % of the cells
at day 14 of the recovery phase (Fig. 4). Therefore, treat-
ment #3 was the most effective at inducing long term
DNA damage after an extended recovery phase.
Therapy-resistant lung cancer cells feature stem-like and
EMT properties
As described above, we found that prolonged MTA pre-
treatment (treatment #3) significantly augmented the in-
hibitory effect of cisplatin on lung cancer cell growth
compared to co-treatment (treatment #1; Fig. 1a) even
during the extended recovery phase (Fig. 1d). At day 17 of
the recovery phase, colonies consisting of dividing cells
were detectable after all tested treatment regimens, al-
though with different frequencies. In detail, compared to
the untreated control, colony formation was reduced by
factor of 1.7, 2.8 and 8.9 after treatment #1/#2/#3, respect-
ively (Fig. 5), which is in agreement with the reduction in
cell numbers reported above (Fig. 1d). Visual examination
revealed that the morphology of the therapy-resistant col-
onies and the cells therein was heterogeneous. However,
we were able to cluster the colonies into three distinct
types based on morphological differences (Fig. 5a). Resist-
ant colonies characterized by tight/continuous boarders,
comprising cells with an embryonic stem cell-like pheno-
type, e.g. high nucleus to cytoplasm ratio, were catego-
rized as type 1 colonies. Colonies consisting of cells with a
low nucleus to cytoplasm ratio, which were not so tightly
packed but still featured continuous boarders, were cate-
gorized as type 2 colonies. Colonies without a continuous
boarder consisting of elongated cells were categorized as
type 3 colonies. Interestingly, visual examination revealed
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that untreated A549 cells seeded at a low density give
rise to colonies with distinct morphological features
with a frequency of 5 %, 50 % and 45 % for colony type
1, 2 and 3, respectively (Fig. 5b). After treatment #1,
the relative fraction of type 3 clones was increased in
the therapy-resistant population (60 %), which was even
further augmented after treatment #2&3 (70 % and
82 %, respectively). However, the absolute number of
colonies was decreased by all three treatment regimens,
with a 5.4-fold reduction after treatment #3 compared
to treatment #1.
We have previously shown that EMT plays a crucial
role in lung cancer chemotherapy resistance [12]. There-
fore, we further determined the expression of EMT
marker genes in the therapy-resistant cells at day 17 of
the recovery phase (Fig. 5c). Expression of the epithelial
marker E-cadherin was decreased in therapy-resistant
cells after all treatment regimens whereas expression of
genes associated with a mesenchymal phenotype, e.g. N-
cadherin and vimentin was increased, and was most pro-
nounced after treatment #3 (Fig. 5c). In agreement, most
of the therapy-resistant colonies after treatment #3 fea-
tured a mesenchymal phenotype (Fig. 5a and b), i.e. loss
of cell-to-cell contact, and they contained spindle-
shaped cells, a characteristic feature of mesenchymal
cells (reviewed in [13]).
The presence of cancer stem cells is also associated
with chemotherapy resistance [24, 25]. We determined
mRNA expression levels of the stemness genes NANOG
and Oct4B, and also of the putative lung cancer stem cell
markers CD44 and CD133 (Fig. 5c). The expression of
all stem cell markers was increased in the therapy-
resistant cells after treatment #1, further enhanced after
treatment #2 and most augmented after treatment #3.
Of note, the expression of NANOG and CD133 was 2.5
and 3 fold increased after treatment #3 compared to
treatment #1, respectively.
In summary, we provide evidence that the inhibitory ef-
fect of MTA-cisplatin combination therapy on lung cancer
cell growth can be further augmented by the optimization
of the treatment schedule. Prolonged MTA pretreatment
preceding cisplatin treatment reduces cell growth and col-
ony formation compared to concomitant treatment, in-
creases the fraction of senescent cells and decreases the
occurrence of aneuploid cells. Furthermore, our investiga-
tions reveal that prolonged MTA-pretreatment enhances
treatment-induced cell cycle arrest and significantly delays
recovery after DNA damage induction. Finally, we have
demonstrated that treatment-resistant colonies display a
mesenchymal-like morphology (colony type 3), with ele-
vated expression of stem cell and EMT-associated genes.
But pretreatment with MTA prior to cisplatin reduces the
Fig. 4 Prolonged MTA pretreatment enhances cisplatin-induced accumulation of persistent DNA damage. Basal H2AX phosphorylation was set at
5 % in untreated controls and used for normalization among experiments as described in the material and methods section. Cell cycle phase-specific
H2AX phosphorylation levels were determined as described in Figure S5. Data shown are the mean values and standard deviations of three
experiments. *Percentage of total cell population (mean from three experiments). neg = γH2AX negative; pos = γH2AX positive
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number of these colonies compared to the standard con-
comitant treatment.
Discussion
A recent retrospective analysis of three phase III ran-
domized controlled trials indicated that concomitant
MTA-cisplatin combination therapy should be consid-
ered as the gold standard treatment for advanced adeno-
carcinoma (reviewed in [1]). The present in vitro study
provides evidence that suggests that pretreatment with
MTA prior to cisplatin is significantly more efficient
than concomitant treatment with both drugs. These re-
sults are in agreement with the study of Kano et al.,
which revealed that exposure of A549 cells to MTA for
24 h and subsequent cisplatin treatment for 24 h
followed by a 72 h recovery phase synergistically reduced
cell survival whereas the inversed treatment regimen or
the simultaneous application of MTA and cisplatin re-
sulted in antagonistic effects [26]. Similarly, 24 h pretreat-
ment with MTA sensitized A549 cells to a subsequent
treatment with a histone deacetylase inhibitor and in-
creased the survival-benefit of the combination treatment
in a patient-derived lung cancer mouse xenograft model
[27]. In addition, MTA pretreatment followed by treat-
ment with a protein kinase Cβ inhibitor was shown to
synergistically reduce cell growth of four NSCLC cell lines
whereas the inverse treatment schedule had an antagonis-
tic effect [28]. Thus, the present results are in agreement
with the general consensus in the literature indicating that
MTA pretreatment sensitizes NSCLC cells to a variety of
cytotoxic drugs. The present study provides for the first
time an in-depth analysis of the effects on NSCLC cells of
the combined treatment of MTA and cisplatin over an ex-
tended recovery period.
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24 h after the end of the treatment phase, cell num-
bers were ~5-fold lower after treatment #1 compared to
treatment #3. Although a short-term recovery analysis
would therefore suggest treatment #1 to be the most ef-
ficient anticancer treatment, treatment #3 was more ef-
fective over a more extended recovery period. Tumor
growth in animal models is usually monitored over pe-
riods of several weeks. However, further studies will be
needed to demonstrate the superior anticancer efficiency
of treatment #3 in vivo.
Controversial results concerning the effect of cell
density, e.g. gap junction intercellular communication,
on survival of cancer cells after treatment with DNA
damaging agents including cisplatin are reported in the
literature [29–31]. At the start of the 24 h cisplatin treat-
ment, cell density was 2.7-fold higher after extensive
pemetrexed pretreatment (treatment #3, day 2) com-
pared to treatment #1 (day 0) (Fig. 1b). However, cell
density was still >4 times below full confluence (Fig. 1b,
untreated control, day 3), which is associated in NSCLC
cell lines with DNA damage resistance [29]. Hence, an
alternative experimental setting will be necessary to elu-
cidate if survival after pretreatment with MTA prior to
cisplatin challenge is significantly altered by variations in
cell culture density.
While increased senescence was observed after treat-
ment #1, as demonstrated by increased β-galactosidase
activity, cell size and granularity, these effects were
much more pronounced after treatment #3. Consistent
with these findings of senescence induction, it has been
shown that MTA-treated malignant mesothelioma cells
also undergo accelerated senescence [32]. Interestingly,
the same study revealed that conditioned media from
senescent MPM cells triggered the emergence of EMT-
like, clonogenic and chemoresistant cell subpopulations.
Senescent cancer cells can be cleared by the immune
system, however the role of senescence in cancer pro-
gression is still debated (reviewed in [17]). Senescence
serves as a physiological barrier against tumor initiation
and progression. On the other hand, senescent cancer
cells might be able to overcome their dormant state
representing a dangerous potential for tumor relapse.
Thus, it will be crucial to utilize an immune competent
animal model to determine the schedule-dependent anti-
cancer efficiency of the combination therapy.
We observed that the three tested treatment regimens
predominantly induced senescence rather than apop-
tosis. In contrast, Yang et al. [33] showed that 60 % of
A549 cells became apoptotic after treatment with 1 μM
MTA for 72 h. Of note is that, the present study esti-
mated the fraction of apoptotic cells based on the sub-
G1 DNA content determined by flow cytometry whereas
Yang et al. performed their analysis by comet assay and
quantification of caspase activity.
It is well-established that the cell cycle status plays a
critical role in the efficiency of combination chemother-
apy. Unperturbed cells are maximally sensitive to cisplatin
treatment during late G1/early S-phase and least sensitive
during peak DNA synthesis (reviewed in [34]). We
showed that treatment with 1 μM MTA alone for 24 h re-
sulted in the accumulation of cells in S-phase, which is in
agreement with a previous study [33]. At the start of the
24-h cisplatin treatment, the fraction of F/S-low cells in S-
phase was highest in treatment #3 (day2) compared to
treatment #2 (day1) and treatment #1 (untreated). The ef-
fect was even more pronounced in F/S-high cells. In
agreement with our observation, Yang et al. also reported
a significant S-phase arrest of A549 cells after treatment
with 1 μM MTA for 48 h [35]. Thus, we observed in-
creased cisplatin sensitivity upon MTA-induced S-phase
arrest, suggesting that it is not the S-phase status per se
but is more likely to be the MTA-induced perturbation of
DNA synthesis, which sensitizes cells to subsequent cis-
platin treatment. Indeed, it has been reported that cells
blocked at the G1/S-boundary remained sensitive to cis-
platin after release of the block [36].
Comprehensive analysis revealed that 10 days after
treatment #1, the cell cycle distribution of the F/S-low
subpopulation was similar to the untreated control
whereas cells were mainly arrested in S/G2/M-phase after
treatment #3. Notably, at day 14 of the recovery phase, all
F/S-low subpopulations displayed normal cell cycle distri-
bution after the three treatment regimens although this
fraction was significantly lower after treatment #3. In sum-
mary, during the extended recovery period, a subpopula-
tion of cells in all three treatment groups overcomes cell
cycle arrest and successfully completes mitosis, as also in-
dicated by the presence of proliferating clones at later re-
covery time points. Thus, this small fraction of cells is
resistant to even the most efficient treatment regimen
tested in this study, even though it is smaller in number
than for other treatments.
It has been previously shown that aneuploidy is associ-
ated with poor prognosis in NSCLC [37, 38]. Interest-
ingly, 14 days after treatment #1&#2, a significant
fraction of (p53-proficient) A549 cells acquired abnor-
mal chromosome content, i.e. became aneuploid, which
was less pronounced after treatment #3. We previously
observed that induction of persistent DNA damage in
p53-deficient HCT116 cells due to REV3 inhibition re-
sults in prolonged mitosis and subsequent return to
interphase without cell division resulting in aneuploidy
[23], which was not observed in p53-proficient HCT166
cells nor A549 cells, independently of p53 status. Thus,
results from the present study suggest that concomitant
MTA-cisplatin treatment might have an adverse effect
on the protective function of p53 upon the induction of
aneuploidy. Treatment #3 not only significantly reduced
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the number of surviving cancer cells but also decreased
the fraction of aneuploid cells in the remaining, therapy-
resistant population.
Treatment of A549 cells with 1 μM MTA for 24/48 h
led to a time dependent increase in H2AX phosphoryl-
ation, which is in agreement with the literature [33, 35].
Simultaneous MTA-cisplatin treatment considerably in-
creased H2AX phosphorylation. Interestingly, after MTA
pretreatment for 24 h (treatment #2, day1), subsequent
cisplatin-MTA treatment for 24 h (treatment #2, day2)
did not further increase H2AX phosphorylation levels
compared to MTA treatment alone (treatment #3, day2).
Furthermore, after MTA pretreatment for 48 h (treat-
ment #3, day2), subsequent cisplatin-MTA treatment for
24 h (treatment #3, day3) resulted in decreased H2AX
phosphorylation levels in F/S-low and also F/S-high cells
independently of the cell cycle status. In this context, it
has been shown that nucleotide depletion leads to se-
questration of replication protein A (RPA), thereby
restricting its availability for nucleotide excision repair
[5], the primary DNA repair system processing cisplatin
adducts. Thus, we hypothesize that MTA-induced nu-
cleotide depletion induces the sequestration of RPA to
single stranded DNA formed at stalled replication forks.
Insufficient RPA levels limit nucleotide excision repair of
cisplatin adducts and subsequent H2AX phosphorylation
[21]. Additional cisplatin treatment may overload mo-
lecular pathways required for the maintenance of the
high γH2AX levels induced by MTA pretreatment, but
further experiments will be required to elucidate the
exact molecular mechanisms involved.
An initial increase in γH2AX phosphorylation was
observed during the recovery phase after treatment #3.
In this context, it has been shown that reduced nucleo-
tide levels in combination with cisplatin treatment lead
to nucleotide excision repair-mediated single-strand
gaps, which are likely to be converted into double-
strand breaks in the subsequent S-phase [39]. Similarly,
treatment with 5-Fluorouracil leads to the incorpor-
ation of 5-Fluorouracil and uracil during S-phase gen-
erating DNA repair-dependent, persistent DNA strand
breaks during the successive G2/M-G1-phase, thereby
interfering with the replication machinery in the subse-
quent S-phase [40]. Thus, the increased levels of H2AX
phosphorylation at the extended recovery time points
after treatment #3 might be due to the persistence of
complex DNA damage or repair intermediates. In this
context, it has been shown before that the persistence
of H2AX phosphorylation 24 h after cisplatin treatment
correlated with the loss of clonogenic potential [41]. In
summary, the analysis of H2AX phosphorylation levels
have provided a first insight into the molecular mecha-
nisms underlying the increased efficiency of the com-
bination therapy after prolonged MTA pretreatment.
Further studies will be necessary to elucidate the exact na-
ture of the resulting DNA damage after prolonged MTA
pretreatment. It has been reported that cell lines contain
subpopulations, which can be identified based on various
features. For example, from parental A549 cells, a subpop-
ulation with increased sphere formation capacity has been
identified based on co-expression of EpCAM/CD166/
CD44 [42]. The current experiments revealed the existence
of three distinct subpopulations in parental A549 cells by
virtue of their capacity to give rise to colonies with diver-
gent morphologies, and we focused on resistant cells sur-
viving the combination treatment. Although the absolute
numbers of all the clone types decreased after combination
therapy, type 3 clones characterized by an enlarged cell size
and mesenchymal morphology were relatively enriched,
most prominently by treatment #3. Formation of type 1&2
clones was almost completely abolished by treatment #3.
Further analysis of the subpopulation surviving treatment
#3 revealed not only the expression of EMT markers but
also that of stemness genes was increased indicating that
the resistant clones have characteristic features associated
with hybrid-E/M state. In agreement with these findings, it
has been shown that cisplatin-resistant NSCLC sublines
displayed a putative stemness signature with increased ex-
pression of CD133/CD44 compared to the corresponding
parental cells [43]. Interestingly, expression of stem cell
markers NANOG, Oct4 and Sox2 were significantly upreg-
ulated in those cells as were the EMT markers c-Met and
Beta-catenin, which is in agreement with a hybrid E/M
state. Further, a hybrid-E/M state was also identified in tu-
mors of different origin, e.g. breast cancer [10] and clear
cell renal cell carcinoma [44]. Since the hybrid-E/M state
was associated with poor survival in breast cancer [10], it
is tempting to speculate that the hybrid-E/M state
might allow tumor cells to more readily differentiate
either to a more mesenchymal phenotype (associated
with invasiveness, metastasis and chemoresistance) or
an epithelial phenotype (associated with metastatic
colonization/proliferation) [45] depending on the de-
mands of the tumor microenvironment [44]. A recent
publication revealed the existence of a hybrid-E/M state in
various lung adenocarcinoma cell lines [46]. Lung adeno-
carcinoma cell lines containing a significant fraction of
hybrid-E/M cells were highly invasive despite gene and
protein expression of epithelial markers. It was proposed
that the hybrid-E/M state is controlled by a regulatory
network consisting of mir-200/Zeb and Snail/miR34 [47].
Thus, our study adds to the growing body of literature
identifying the hybrid-E/M state and its regulatory switch
as a potential therapeutic target for cancer therapy
(reviewed in [48]). From a pragmatic point of view, we
established in this study a protocol to efficiently select a
subpopulation consisting of highly resistant lung cancer
cells characterized by a hybrid-E/M state, which, at least
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in breast cancer, is associated with poor survival. Add-
itional experiments will be necessary to elucidate whether
the increase in cells featuring a hybrid-E/M state is due to
a treatment-induced selection process or if the treatment
regimen induces gene expression changes in clone type 3
cells, e.g. increased expression of stem cell genes.
Our study was limited to the analysis of the cell line
A549 containing an activating mutation of the KRAS
oncogene. In lung adenocarcinoma, oncogenic KRAS
mutations are highly prevalent (~25 %) but therapy
choices are very limited (reviewed in [49]) indicating
that our findings might be of relevance to improve
treatment of a significant fraction of lung adenocar-
cinoma patients. However, further analysis of cell lines
and primary cultures containing alternative mutational
signatures will be necessary to evaluate if these find-
ings are also of relevance for different lung cancer
subsets.
Currently, MTA is administered as a daily 10-min in-
fusion, which results in a relative rapid clearance from
the body. However, MTA is rapidly converted intracellu-
larly to its active form by polyglutamation. Thus, active
MTA polyglutamate derivatives are sustained in tumor
cells long after the MTA blood levels have declined,
explaining the clinical efficiency of the initial phase I tri-
als with single-agent MTA therapy, which was adminis-
tered on day 1 every 21 days for up to 6 cycles (reviewed
in [50]). The present study reveals that prolonged MTA
pretreatment increases the efficiency of the combination
therapy in vitro. Hence, it is tempting to speculate that a
delayed cisplatin administration might also increase the
efficiency of the MTA-cisplatin combination therapy in
the clinical setting.
Conclusions
The present study has revealed that the efficiency of
the MTA-cisplatin combination therapy can be aug-
mented in vitro by optimizing the treatment schedule.
The increased efficiency after prolonged MTA pre-
treatment is attributed to the induction of persistent
DNA damage, which in turn results in increased apop-
tosis and senescence initiation thereby ultimately
diminishing the occurrence of resistant clones. There-
fore, our study warrants further experiments to eluci-
date whether an optimization of the standard therapy
schedule might also potentiate the current combin-
ation treatment regimen in vivo. In addition, the
remaining, therapy resistant cells not only exhibited a
mesenchymal phenotype but also featured an increased
expression of stem cell markers, both distinct hall-
marks of a hybrid-E/M state. Thus, our research is the
starting point for future in-depth analysis of this
therapy-resistant subpopulation in lung cancer.
Additional files
Additional file 1: Figure S1. Optimization of the treatment schedule
potentiates MTA-cisplatin anticancer efficacy. Representative image of a
large H460 clone (indicated by the arrow after treatment #1) and a small
clone (indicated by the arrow after treatment #2) at day 10 of the recovery
phase. Quantification of clones was performed as described in the material
and methods section. (PPTX 230 kb)
Additional file 2: Figure S2. Flow cytometric analysis of forward (cell size)
and side (cellular granularity) scatter intensity as an alternative readout for
senescence. Approximately 5 % of the cells of the untreated controls were
placed in the F/S-high compartment and used as normalization standard as
described in the material and methods section. Forward and side scatter
analysis by flow cytometry (without reseeding) at the indicated time points
during the treatment and recovery phase. Shown are representative images
of three experiments. (PPTX 389 kb)
Additional file 3: Figure S3. MTA-cisplatin treatment leads to increased
cell size (FSC) and granularity (SSC) thereby influencing DAPI signal
intensity. A549 cells were concomitantly treated with MTA-cisplatin for
24 h and subsequently analyzed by flow cytometry. A Subpopulations
featuring either normal forward and side scatter intensity (F/S-low) or
increased forward and side scatter intensity (F/S-high) are indicated by
the blue and red gates, respectively. B Histogram blots of DNA content
from F/S-low and F/S-high subpopulations. Specific cell cycle phases of
the F/S-low and F/S-high subpopulations are indicated by the blue and
red gates, respectively. C Cell cycle phase-specific H2AX phosphorylation
was determined by the same cell cycle gating strategy as shown in B in
combination with applying the 5 % threshold for basal H2AX phosphorylation
levels as indicated in the material and methods section. (PPTX 376 kb)
Additional file 4: Figure S4. MTA treatment abolishes DNA replication.
Treatment of A549 cells with 1 μM MTA for the indicated time points.
DNA replication, indicated by EdU incorporation, and cellular DNA content
(DAPI) were detected simultaneously by flow cytometry. (PPTX 62 kb)
Additional file 5: Figure S5. Applied strategy to determine cell cycle
phases and cell cycle phase-specific H2AX phosphorylation levels by flow
cytometry. To determine more accurately the G1 to S- and the S to G2/
M-borders of the cell cycle phases from cell populations with irregular
cell cycle distributions, H2AX phosphorylation over DNA content was
blotted as “zebra blots” as described in the text. Shown are specific cell
cycle gates indicated in blue for the F/S-low subpopulations of untreated
controls. Specific cell cycle gates indicated in red are shown for the F/
S-high subpopulations of treated samples. A 5 % threshold for basal
H2AX phosphorylation levels was applied as indicated in the material
and methods section. Analysis was performed after 24 h of MTA and cisplatin
co-treatment, e.g. treatment #1, day 1. Data shown are representative of three
experiments. (PPTX 104 kb)
Additional file 6: Figure S6. Applied strategy to determine cell cycle
phases of subpopulations by flow cytometry. Flow cytometric analysis
was performed at the indicated time points and subpopulations
featuring either increased forward and side scatter intensity (F/S-high) or
normal forward and side scatter intensity (F/S-low) were identified as
indicated in Supplementary Figure S3. Cell cycle analysis was performed
independently for F/S-low and F/S-high cells. Gates set to determine the
cell cycle distribution of F/S-low and F/S-high subpopulations were
determined as described in Figure S5 and are indicated in blue and red,
respectively. Indicated are days (d) during treatment and the recovery phase
(rec d). Data shown are representative of three experiments. (PPTX 386 kb)
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